Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis

Basit Öğe Kaydı
dc.contributor.authorAkarca, Funda Karbek
dc.contributor.authorCan, Ozge
dc.contributor.authorYalcinli, Sercan
dc.contributor.authorAltunci, Yusuf Ali
dc.date.accessioned2019-10-27T10:47:19Z
dc.date.available2019-10-27T10:47:19Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractOwing to the advancements in medicine, new information is obtained regarding cancer, new antineoplastic agents are developed. Frequent use of these new pharmacological agents emergency physicians to be vigilant about their side effects. We present a case of adrenal crisis in a patient with non-small cell lung cancer (NSCLC), caused by an immunomodulatory drug; nivolumab. While adverse events are related to other immunomodulatory drugs have been reported in literature, our case is the first nivolumab-related adrenal failure to be reported. A patient with lung cancer presented to the emergency room(ER) with nausea and vomiting. Hyponatremia, hyperkalemia, persistent hypoglycemia led to the diagnosis of adrenal crisis. Having direct effect on the immune system, these drugs were claimed to be highly reliable. However, there is no reliable data on the side effect profile of these agents. It should be kept in mind that life-threatening auto-immune reactions may occur. Copyright (C) 2017 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license.en_US
dc.identifier.doi10.1016/j.tjem.2017.05.007en_US
dc.identifier.endpage159en_US
dc.identifier.issn2452-2473
dc.identifier.issue4en_US
dc.identifier.pmid29464222en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage157en_US
dc.identifier.urihttps://doi.org/10.1016/j.tjem.2017.05.007
dc.identifier.urihttps://hdl.handle.net/11454/31407
dc.identifier.volume17en_US
dc.identifier.wosWOS:000424190600010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofTurkish Journal of Emergency Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNivolumaben_US
dc.subjectImmunomodulationen_US
dc.subjectCTLA 4 antigenen_US
dc.subjectAdrenal crisisen_US
dc.titleNivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu